Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi/Aventis Merger Would Prevent Plavix-Style Profit-Sharing Agreements, CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi downplays Aventis' sales force as a major reason for merging with its French neighbor. Sanofi has nine late-stage products, including the smoking cessation/obesity agent rimonabant and antiarrhythmic dronedarone.

You may also be interested in...



Sanofi Plans To Add Two NMEs To Phase III In 2004, Bringing Total To Nine

Antidepressant saredutant and hyponatremia agent SR 121463 are ready to proceed to final stage of development after successful Phase IIb results. Combined with merger target Aventis, Sanofi's current total would be 12 novel Phase III agents, rivaled only by Pfizer.

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.

Topics

UsernamePublicRestriction

Register

PS058623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel